Wells Fargo’s Anixa Biosciences ANIX Stock Holding History

Wells Fargo’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31K	Hold	12,000	–	–	﹤0.01%	5622
2025 Q4	$37.4K	Buy	12,000 +1,500	+14%	+$6.14K	﹤0.01%	5638
2025 Q3	$34.6K	Hold	10,500	–	–	﹤0.01%	5657
2025 Q2	$34.6K	Buy	10,500 +2,000	+24%	+$5.71K	﹤0.01%	5633
2025 Q1	$24.3K	Hold	8,500	–	–	﹤0.01%	5644
2024 Q4	$19.7K	Hold	8,500	–	–	﹤0.01%	5772
2024 Q3	$26.8K	Hold	8,500	–	–	﹤0.01%	5556
2024 Q2	$18.8K	Buy	8,500 +7,752	+1,036%	+$22K	﹤0.01%	5605
2024 Q1	$2.33K	Buy	748 +9	+1%	+$36	﹤0.01%	6003
2023 Q4	$2.87K	Buy	739 +13	+2%	+$44	﹤0.01%	6038
2023 Q3	$2.37K	Buy	726 +3	+0.4%	+$10	﹤0.01%	6070
2023 Q2	$2.31K	Buy	723 +9	+1%	+$35	﹤0.01%	6191
2023 Q1	$3.07K	Sell	714 -995	-58%	-$4.36K	﹤0.01%	6162
2022 Q4	$7.26K	Buy	1,709 +1,007	+143%	+$4.84K	﹤0.01%	5669
2022 Q3	$3K	Hold	702	–	–	﹤0.01%	6023
2022 Q2	$3K	Buy	702 +17	+2%	+$54	﹤0.01%	6153
2022 Q1	$2K	Buy	685 +1	+0.1%	+$3	﹤0.01%	6643
2021 Q4	$2K	Sell	684 -5,501	-89%	-$22.2K	﹤0.01%	6859
2021 Q3	$30K	Sell	6,185 -5	-0.1%	-$23	﹤0.01%	5818
2021 Q2	$24K	Buy	6,190 +31	+0.5%	+$132	﹤0.01%	5824
2021 Q1	$29K	Buy	6,159 +5,013	+437%	+$24K	﹤0.01%	6041
2020 Q4	$3K	Sell	1,146 -6,040	-84%	-$15.2K	﹤0.01%	6219
2020 Q3	$17K	Sell	7,186 -778	-10%	-$2.01K	﹤0.01%	5787
2020 Q2	$24K	Sell	7,964 -119	-1%	-$247	﹤0.01%	5656
2020 Q1	$13K	Buy	8,083 +113	+1%	+$331	﹤0.01%	5693
2019 Q4	$26K	Sell	7,970 -100	-1%	-$367	﹤0.01%	5683
2019 Q3	$33K	Hold	8,070	–	–	﹤0.01%	5675
2019 Q2	$29K	Buy	8,070 +1,100	+16%	+$4.65K	﹤0.01%	5702
2019 Q1	$32K	Sell	6,970 -201	-3%	-$958	﹤0.01%	5416
2018 Q4	$29K	Sell	7,171 -250	-3%	-$1.07K	﹤0.01%	5682
2018 Q3	$35K	Buy	7,421 +6,520	+724%	+$24.5K	﹤0.01%	5704
2018 Q2	$3K	Hold	901	–	–	﹤0.01%	6132
2018 Q1	$4K	Hold	901	–	–	﹤0.01%	6087
2017 Q4	$2K	Hold	901	–	–	﹤0.01%	6172
2017 Q3	$2K	Sell	901 -1,616	-64%	-$1.78K	﹤0.01%	6135
2017 Q2	$3K	Hold	2,517	–	–	﹤0.01%	5994
2017 Q1	$8K	Buy	2,517 +1,866	+287%	+$8.02K	﹤0.01%	5922
2016 Q4	$4K	Hold	651	–	–	﹤0.01%	5977
2016 Q3	$3K	Buy	651 +151	+30%	+$503	﹤0.01%	5988
2016 Q2	$2K	Hold	500	–	–	﹤0.01%	5935
2016 Q1	$2K	Hold	500	–	–	﹤0.01%	6018
2015 Q4	$2K	Hold	500	–	–	﹤0.01%	6003
2015 Q3	$2K	Buy	+500	New	+$2.32K	﹤0.01%	5971

Other funds holding ANIX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo's ANIX Position: Q1 2026 in Review

Wells Fargo held its Anixa Biosciences (ANIX) position steady in Q1 2026 at 12,000 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #5622.

Wells Fargo first reported a position in ANIX in Q3 2015 and has held it in 43 quarters since. The position peaked at $37.4K in Q4 2025. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

Wells Fargo held 12,000 shares of Anixa Biosciences worth $31K as of Q1 2026.
Wells Fargo left its Anixa Biosciences share count unchanged in Q1 2026.
Anixa Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5622 holding.
Wells Fargo first reported a position in Anixa Biosciences in Q3 2015 and has held it in 43 quarters since.
Wells Fargo's Anixa Biosciences position peaked at $37.4K in Q4 2025.
60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.